Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	21.65	28.79	53.08	89.02	130.09
Cash & Cash Equivalents	21.65	28.79	53.08	89.02	130.09
Cash Growth	-24.80%	-45.76%	-40.38%	-31.57%	98.08%
Other Current Assets	0.87	1.37	3.51	3.4	2.96
Total Current Assets	22.52	30.15	56.58	92.42	133.04
Property, Plant & Equipment	0.09	0	0.21	0.36	0.56
Other Long-Term Assets	0.04	0	0.03	0.03	0
Total Long-Term Assets	0.13	0	0.24	0.39	0.56
Total Assets	22.65	30.16	56.82	92.81	133.61
Accounts Payable	1.67	0.84	1.77	4.5	2.18
Deferred Revenue	0.53	0	0	0	0
Current Debt	0	0	0.19	0.26	0.24
Other Current Liabilities	2.19	2.36	5.35	10.57	6.64
Total Current Liabilities	4.39	3.2	7.32	15.33	9.06
Long-Term Debt	0	0	0	0.08	0.3
Other Long-Term Liabilities	1.31	1.31	0	0	0
Total Long-Term Liabilities	1.31	1.31	0	0.08	0.3
Total Liabilities	5.7	4.51	7.32	15.41	9.36
Total Debt	0	0	0.19	0.34	0.54
Debt Growth	-	-	-43.17%	-38.50%	-
Retained Earnings	-308.08	-293.8	-181.13	-144.01	-90.53
Comprehensive Income	-10.61	-10.62	-10.36	-10.04	-11.53
Shareholders' Equity	16.95	25.64	49.51	77.4	124.24
Net Cash / Debt	21.65	28.79	52.89	88.68	129.54
Net Cash / Debt Growth	-24.80%	-45.57%	-40.37%	-31.54%	97.25%
Net Cash Per Share	5.98	17.37	49.69	83.93	431.63
Working Capital	18.14	26.95	49.27	77.09	123.98
Book Value Per Share	4.69	15.47	46.52	73.24	413.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).